Tradestie Institutional Equity Comparison Engine
ENTX vs KTTA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (2โ0 Pillars ยท 5โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus KTTA at N/M Forward P/E and 0.0% operating margin (+1498.1% YoY). In options structure, ENTX sits in CONSOLIDATION (33rd %ile IV; Dealer Gamma Walls on Pro) against KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ENTX N/M vs KTTA N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY -100.0% vs +1498.1%
Momentum & Technical Winner
ENTX
1Y +24.7% vs +0.6% ยท 52W Pos 73% vs 11%
Options & Structure Winner
ENTX
CONSOLIDATION (33rd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap
$571.2M
1M Return
+9.44%
1Y Return
+24.72%
Forward P/E
N/M
Unified AI Score
47.5 / 100
HOLD
Tech 52.0
Fund 49.0
Flow 72.0
Mom 50.0
KTTA
NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap
$17.7M
1M Return
+7.52%
1Y Return
+0.59%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ENTX +24.72%
KTTA +0.59%
Spread: +24.13 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | KTTA Revenue | ENTX Op. Margin | KTTA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -3059.7% | N/A | ENTX |
| FY2021 | $0M | $0M | -2139.6% | -29925.7% | ENTX |
| FY2022 | $0M | $0M | -9714.2% | -2587.3% | KTTA |
| FY2024 | $0M | N/A | -5295.6% | N/A | ENTX |
| FY2025 | $0M | N/A | -27450.0% | N/A | ENTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTX | KTTA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $571.2M | $17.7M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | +1498.1% | Higher Growth | KTTA |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -20.3% | -88.8% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 73% ($1โ$4) | 11% ($0โ$2) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 53% Vol | 0.68ฮฒ ยท 185% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 47.5 / 100 (HOLD) | 42.1 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ENTX vs KTTA Buy Guide
ENTX
CONSOLIDATION
83d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
33rd %ile
IV Regime
Balanced (25thโ60th %ile)
KTTA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ENTX nor KTTA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.